Dr. Wrubel has ten years of experience in venture capital and has been associated with a large number of private companies, including such now publicly traded companies as Pozen Pharmaceuticals, OraPharma, and GenVec. Prior to starting Foundation Medical Partners, Dr. Wrubel was an investment professional with Canaan Partners and more recently Highland Capital Partners,where he specialized in biotechnology and medical device investments. Dr. Wrubel serves on the board of directors of EndoGastric Solutions, Inc.,CardioMEMS, Inc.,IlluminOss and Circulite, Inc.
Mr. Woodall is the Chief Executive Officer of the Cardiovascular Research Foundation (CRF). Founded in 1991, CRF has played a key role in the development of nonsurgical and drug-based treatments of heart and vascular diseases. </br>
During a critical era in the development of the subspecialty of interventional cardiology, from 1988 until 1996, he held the office of President of Interventional Systems Company (a division of Johnson & Johnson), leading the team responsible for developing the company's cardiovascular franchise into a $1 billion division. His tenure there included the development and launch of the PALMAZ-SCHATZCoronary Stent, which was designated as "the most important new medical device in the past 15 years" in a survey of medical device company CEOs in 1996. Mr. Woodall retired from Johnson & Johnson in 2001 and became the Chairman of the Board of the Lehigh Valley Hospital and Health Network, which has received multiple awards as one of the leading hospital systems in America. He has served on the Board of Directors for Doylestown Hospital. Mr. Woodall also serves on the Board of Directors of the Cardiovascular Research Foundation in New York City, the International Society of Endovascular Specialists in Phoenix, and CardioMEMs Inc., a cardiovascular device company in Atlanta.
Dr. Fortune has over 30 years of experience in the healthcare, life sciences and information technology sectors including R&D, business development, manufacturing, information technology and general management responsibilities. He has been a Partner at Boston Millennia Partners since 2002. He was previously President and Chief Operating Officer of New Era of Networks (Nasdaq: NEON); Vice President at Monsanto; Vice President at Bristol Myers Squibb; Group President at Baxter International; and VP R&D at Baxter International. Dr. Fortune, currently serves on the boards of directors of CombinatoRx, Inc. (NasdaqGM: CRXX) and PAREXEL International Corp. (NasdaqGS: PRXL) as well as several private life sciences companies. He has been responsible for nurturing start-up activities from idea to prototype to standalone business and has been involved in some 30 M&A transactions from sourcing the company to closing the deal and ensuring successful integration. Dr. Fortune has also served on the engineering and scientific advisory boards of the University of Wisconsin, the University of Illinois, and the University of Chicago, and currently serves on the Industrial Advisory Board of the Cleveland Clinic Foundation and on the Commercial Advisory Board of the Global Cardiovascular Innovation Center of the Cleveland Clinic. He holds a B.A. from the University of Wisconsin, an MBA from Northwestern University, and a Ph.D. in Physical Chemistry from the University of Wisconsin.
CircuLite, Direct Flow Medical, EndoGastric Solutions, GenVec, Histogenics, IlluminOss Medical, and Rise Health
Collegium Pharmaceutical, Histogenics, and PreCision Dermatology